Cyclerion Therapeutics Enters into Exclusive Negotiation Period and Binding Equity Investment Agreement
April 03, 2023 07:30 ET
|
Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass., April 03, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) today announced that the Board of Directors of the Company, acting solely by all of its independent...
Cyclerion Therapeutics to Share CY6463 MELAS Topline Study Results, CHOP to Present CY6463 Preclinical Data at UMDF Mitochondrial Medicine 2022 Symposium
June 06, 2022 07:00 ET
|
Cyclerion Therapeutics, Inc.
Topline results to be shared during the clinical trial update platform session CHOP preclinical data demonstrates CY6463-induced functional improvement in zebrafish disease models CAMBRIDGE, Mass.,...
Cyclerion Therapeutics Appoints Errol De Souza, Ph.D., to Board of Directors
April 26, 2021 07:00 ET
|
Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass., April 26, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive...
Cyclerion Announces Leadership Transitions
December 21, 2020 07:30 ET
|
Cyclerion Therapeutics, Inc.
Anjeza Gjino promoted to Chief Financial Officer; Bill Huyett to transition to Strategic Advisor Cheryl Gault promoted to Chief Operating Officer Amy Schulman stepping down from Board of Directors ...